Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
J Exp Biol ; 225(16)2022 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-35994028

RESUMO

Elasmobranch fishes (sharks, skates and rays) consume prey of a variety of sizes and properties, and the feeding mechanism typically reflects diet. Spotted ratfish, Hydrolagus colliei (Holocephali, sister group of elasmobranchs), consume both hard and soft prey; however, the morphology of the jaws does not reflect the characteristics typical of durophagous elasmobranchs. This study investigated the mechanical properties and morphological characteristics of the jaws of spotted ratfish over ontogeny, including strain, stiffness and second moment of area, to evaluate the biomechanical function of the feeding structures. Compressive stiffness of the jaws (E=13.51-21.48 MPa) is similar to that of silicone rubber, a very flexible material. In Holocephali, the upper jaw is fused to the cranium; we show that this fusion reduces deformation experienced by the upper jaw during feeding. The lower jaw resists bending primarily in the posterior half of the jaw, which occludes with the region of the upper jaw that is wider and flatter, thus potentially providing an ideal location for the lower jaw to crush or crack prey. The mechanical properties and morphology of the feeding apparatus of spotted ratfish suggest that while the low compressive stiffness is a material limit of the jaw cartilage, spotted ratfish, and perhaps all holocephalans, evolved structural solutions (i.e. fused upper jaw, shape variation along lower jaw) to meet the demands of a durophagous diet.


Assuntos
Tubarões , Rajidae , Animais , Fenômenos Biomecânicos , Comportamento Alimentar , Peixes , Arcada Osseodentária/anatomia & histologia , Tubarões/anatomia & histologia , Rajidae/anatomia & histologia
2.
Acta Oncol ; 50(5): 611-20, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21314297

RESUMO

The current paper presents Chapter 5 of the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening, which deals with the histopathological diagnosis of lesions of the uterine cervix. It completes a series of publications in journals containing the contents of other parts of the European Guidelines. Histopathology provides the final diagnosis on the basis of which treatment is planned, and serves as the gold standard for quality control of cytology and colposcopy. It is also the source of the diagnostic data stored at the cancer registry and used for evaluation of screening programmes. It is therefore important that histopathology standards are monitored and based on agreed diagnostic criteria. Histology is required to diagnose the degree of abnormality in women with persistent low-grade abnormalities including HPV-lesions, as well as high-grade lesions. Cytology may also suggest either glandular abnormalities or be suggestive of high-grade CIN, AIS or invasive cancer. Histopathologists should be aware of, and familiar with, the nature of cytological changes which may be relevant to their reports. The accuracy of the histopathological diagnosis of tissue specimens depends on adequate samples, obtained by colposcopically directed punch biopsies (with endocervical curettage if necessary) or excision of the transformation zone or conisation. An accurate histological diagnosis further depends on appropriate macroscopic description, technical processing, microscopic interpretation and quality management correlating cytological and histological diagnosis. This paper proposes guidelines for sampling and processing of cervical tissue specimens obtained by biopsy, excision and/or curettage.


Assuntos
Colo do Útero/patologia , Colposcopia/métodos , Colposcopia/normas , Técnicas Citológicas/normas , Guias de Prática Clínica como Assunto , Garantia da Qualidade dos Cuidados de Saúde , Europa (Continente) , Feminino , Humanos , Programas de Rastreamento/métodos , Programas de Rastreamento/normas , Esfregaço Vaginal/métodos , Esfregaço Vaginal/normas
4.
Eur Arch Otorhinolaryngol ; 266(2): 261-5, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19057923

RESUMO

Multidisciplinary meetings (MDMs) are an essential part of the management of head and neck cancer. Practice care guidance set up by the British Association of Head and Neck Oncologists has recommended that MDMs should have appropriate projection equipment for computer-generated images so that all members of group have access to the same information. The aim of this paper is to review our experience with the integrated visual presentation of head and neck oncology patients and to demonstrate its advantages over conventional approaches. Digital photographs are taken of patients and of their index tumour at presentation or at the time of diagnostic endoscopy. All relevant pre-treatment digitised images from tumour sites and radiological images and histological slides are incorporated into a single presentation using Microsoft PowerPoint software. During the past 2 years, on-line radiological scans have also become accessible for the meeting to aid treatment planning. Subsequently, all peri-operative pictures and post-surgical macroscopic and microscopic histopathological images are added to each patient's presentation, which is then hyperlinked into the agenda. The Guy's and St Thomas' Head and Neck Cancer Centre treats over 400 patients a year, and since 2002, all new cancer diagnoses have been discussed in the weekly MDM as described above. A total of 1,638 presentations have been incorporated in a centralized database that is updated in the event of recurrence, further primary tumours or other clinical developments. Satisfactory documentation and staging of head and neck tumours must include a verbal description, accurate measurement, diagrammatic representation, photographic recording and appropriate radiological imaging. Integrated presentation at MDM collates all relevant findings for clinical management decisions on patients with head and neck cancer. This approach is also an extremely valuable adjunct to long-term clinical monitoring.


Assuntos
Meios de Comunicação , Neoplasias de Cabeça e Pescoço/diagnóstico , Neoplasias de Cabeça e Pescoço/terapia , Equipe de Assistência ao Paciente , Centros Médicos Acadêmicos , Biópsia por Agulha , Institutos de Câncer , Administração de Caso , Quimioterapia Adjuvante , Terapia Combinada , Prestação Integrada de Cuidados de Saúde/métodos , Diagnóstico por Imagem/métodos , Feminino , Humanos , Comunicação Interdisciplinar , Masculino , Estadiamento de Neoplasias , Radioterapia Adjuvante , Sensibilidade e Especificidade , Reino Unido
5.
J Am Soc Cytopathol ; 8(6): 324-332, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31523013

RESUMO

INTRODUCTION: A historical audit of 30 post-treatment cervical cancers (10% of 289 cancers, 1999-2016) compared with a one-year-equivalent control group treated for cervical intraepithelial neoplasia (CIN) grade 3 (n = 164). MATERIALS AND METHODS: We compared history and follow up of cancer patients and controls and reviewed initial excision biopsies preceding cancer and, in 41% of controls, high-grade recurrence (n = 17) or consistently negative follow-up (n = 51). RESULTS: Either abnormal post-excision cytology without high-risk human papillomavirus (hrHPV) tests or immediate re-excision was recorded in 70% (19 of 27) of patients with squamous cell carcinoma (SCC). Negative investigations including cytology, colposcopy, re-excision, hysteroscopy, hrHPV, and/or treatment default were recorded in 83% (25 of 30) of all cancers. The mean interval between initial excision and cancer diagnosis was 79.8 ± 30.1 months versus 11.2 ± 30.1 months for CIN3 recurrence. Eight, 13, and 9 patients with cancer had initial excision at age 20-34, 35-49, and 50+ years, respectively, compared with 71%, 23%, and 5% of controls. CIN3 more often preceded SCC than CIN2 (22:1); 5 of 30 initial excisions were originally reported as negative after severe dyskaryosis. No SCC or CIN3 recurrence followed complete excision. Depth of CIN3 2+ mm (20 of 82 reviewed) was strongly associated with cancer/high-grade recurrence or early stromal invasion on review (18 of 20; 90%). Discrepancies were found on review in 10% of biopsies and as occasional abnormal cells in 9 of 34 cytology slides. CONCLUSIONS: Residual disease may be inconspicuous or absent on cytology, colposcopy, and/or histology. Management taking account of risk of recurrence (age, CIN3 depth, incomplete initial excision) could avoid some post-treatment cancers.


Assuntos
Displasia do Colo do Útero/terapia , Neoplasias do Colo do Útero/etiologia , Neoplasias do Colo do Útero/patologia , Adulto , Fatores Etários , Biópsia , Estudos de Casos e Controles , Feminino , Seguimentos , Humanos , Margens de Excisão , Pessoa de Meia-Idade , Gradação de Tumores , Invasividade Neoplásica , Recidiva Local de Neoplasia/patologia , Células Estromais/patologia , Neoplasias do Colo do Útero/diagnóstico , Adulto Jovem
6.
J Fam Plann Reprod Health Care ; 34(1): 21-5, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18201402

RESUMO

BACKGROUND: The English National Health Service Cervical Screening Programme (NHSCSP) recommendation not to offer cervical screening to women aged 20-24 years is considered in the context of national rates of cervical intraepithelial neoplasia grade 3 (CIN3) and invasive cervical carcinoma, falling screening coverage in young women, detection of screen-detected invasive cancers and risks of excisional treatment of CIN. METHODS: Registrations of invasive and in situ cervical carcinoma were obtained from the Office for National Statistics, data on screening coverage and cytology results from the NHSCSP website and data on screen-detected cancers from an audit at Guy's & St Thomas' NHS Foundation Trust (GSTFT). RESULTS: Before and after the introduction of organised screening in England, CIN3 was primarily detected in women aged 20-39 years. Increasing rates of CIN3 were recorded in women aged 20-24 years during the last decade (3000-4000 cases per year) despite falling screening coverage. The peak incidence of invasive cancer in screening age groups is now 35-39 years. At GSTFT in 1999-2006, 24 of 32 cancers (75%) in women aged 20-34 years were screen-detected and that percentage declined in subsequent 15-year age bands (p < or =0.0001). DISCUSSION AND CONCLUSIONS: Delaying the age for screening eligibility carries a risk of CIN becoming more extensive, and therefore more difficult to excise, as well as a risk of progression. The NHSCSP should reconsider its decision and encourage young women to be screened, not excluding those aged 20-24 years. Facilities for taking the tests should be made more convenient. Women should be informed that low-grade CIN is potentially reversible and may safely be monitored. Cervical screening also provides an opportunity for education on healthy lifestyles and safer sex while treatment should be reserved for high-grade CIN.


Assuntos
Programas de Rastreamento/estatística & dados numéricos , Neoplasias do Colo do Útero/diagnóstico , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Motivação , Aceitação pelo Paciente de Cuidados de Saúde , Sistema de Registros , Medicina Estatal , Reino Unido/epidemiologia , Displasia do Colo do Útero/diagnóstico , Displasia do Colo do Útero/epidemiologia
7.
Cent Eur J Public Health ; 16(1): 38-40, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18459479

RESUMO

National and international experts in cervical cancer prevention met at the International Workshop on Human Papillomaviruses and Consensus Recommendations for Cervical Cancer Prevention to review the current evidence and assess the potential for improvement in cervical cancer prevention and to develop plans for implementation of cervical cancer prevention programmes in Croatia. Key recommendations were developed and adopted during the course of the meeting. The process of bringing national experts together with internationally recognized experts in an open forum for the development of consensus recommendations could serve as a model for other countries seeking to implement or improve cervical cancer prevention programmes.


Assuntos
Alphapapillomavirus/crescimento & desenvolvimento , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/uso terapêutico , Neoplasias do Colo do Útero/prevenção & controle , Conferências de Consenso como Assunto , Feminino , Humanos , Programas de Rastreamento , Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/virologia
8.
Zoology (Jena) ; 129: 54-58, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30170748

RESUMO

Durophagy in chondrichthyan fishes is thought to entail a set of morphological characteristics, such as hypertrophied adductor muscles, molariform teeth, and high bite forces. However, these characteristics are not common to all durophagous chondrichthyans. In some durophagous chondrichthyans, the jaws are better suited biomechanically to resist bending in the area where prey is processed. Resistance to bending is in part, quantified by second moment of area (I), which uses the neutral axis of an object to analyze the arrangement of material. This study investigated whether the lower jaw of the bonnethead shark, Sphyrna tiburo, is more resistant to bending under the crushing/molariform teeth compared to the grasping teeth. Using computerized tomography (CT) scanning, the jaws of ten bonnethead sharks were visualized, then digitally resliced at identical positions along the jaw for all specimens. I increased along the lower jaw from anterior to posterior as the teeth transform from grasping to crushing, with the largest absolute increase occurring about the transition from grasping to crushing teeth. When the lower jaw is compared to that of a rod of similar cross-sectional area, the shape exceeds that of a rod by 1.6 to 5.7 times, meaning the shape of the jaw is better suited to resist bending than if the same size jaw was shaped as a solid rod. These results suggest the lower jaw of S. tiburo is adapted to resist bending more under the molariform teeth where crushing occurs than at the anterior grasping teeth.


Assuntos
Arcada Osseodentária/fisiologia , Tubarões/fisiologia , Animais , Fenômenos Biomecânicos , Feminino , Masculino , Dente
9.
J Fam Plann Reprod Health Care ; 33(3): 171-6, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17609075

RESUMO

BACKGROUND AND METHODOLOGY: This observational study aimed to establish prevalence of high-risk human papillomaviruses (hrHPV) in women attending three inner London community clinics for routine screening and to pilot hrHPV testing in the triage of either borderline or negative cytology after previous abnormalities. Hybrid Capture 2 was carried out on brush samples taken alongside conventional smears from 1434 women aged 20-49 years. hrHPV positivity prompted earlier referral of women with previous abnormalities and either low-grade or negative cytology. Outcome at colposcopy was compared with the records of 1871 women aged 20-49 years attending colposcopy during the same period of time (routine colposcopies). RESULTS: hrHPV was detected in 111/161 (68.9%) women with abnormal cytology, 76/460 (16.5%) with negative cytology after previous abnormalities and 105/813 (12.9%) with negative cytology and no previous abnormalities. Overall, hrHPV was detected in 292/1434 (20.4%) women in the study (95% CI 18.3-22.5). hrHPV prevalence increased with severity of cytological abnormality (p<0.001) and decreased with age both with negative and low-grade cytology (p<0.001). High-grade cervical intraepithelial neoplasia (CIN) biopsies were found more frequently in women in the study groups with low-grade (p<0.001) or negative cytology than in routine colposcopies, but more women in the study groups attended colposcopy (8.2% compared with 4.1% routine colposcopies, p<0.001). CONCLUSIONS: hrHPV positivity increased detection of high-grade CIN in the study groups at the expense of more colposcopies. hrHPV negativity could reduce the need for investigation of low-grade cytology in women aged over 35 years and for surveillance after previous abnormalities.


Assuntos
Serviços de Saúde Comunitária , Programas de Rastreamento , Teste de Papanicolaou , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/epidemiologia , População Urbana/estatística & dados numéricos , Esfregaço Vaginal , Adulto , Distribuição por Idade , Colposcopia , DNA Viral/isolamento & purificação , Feminino , Humanos , Londres/epidemiologia , Programas de Rastreamento/métodos , Pessoa de Meia-Idade , Papillomaviridae/genética , Infecções por Papillomavirus/complicações , Projetos Piloto , Vigilância da População , Prevalência , Displasia do Colo do Útero/epidemiologia , Displasia do Colo do Útero/prevenção & controle , Displasia do Colo do Útero/virologia
10.
Coll Antropol ; 31 Suppl 2: 41-6, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17598504

RESUMO

The first part of this article will provide an overview of cervical cancer screening in the UK during the years before, during and after the introduction of a highly successful centrally organised cervical screening programme in 1988: since then the incidence of invasive cervical cancer has fallen by more than 40%. Screening was introduced in a background of opportunistic screening with poor quality control during a period of time when risk of disease was increasing, which will be demonstrated by national registrations of carcinoma in situ as well as invasive cancer. The programme is still facing new challenges and has recently recorded falling screening coverage in younger women, the causes of which have yet to be established. Liquid-based cytology is in the process of being rolled out nationally but high-risk human papillomavirus testing has yet to be introduced into the National Health Service (NHS) programme. Lessons from our experience may be relevant to countries introducing and maintaining organised programmes elsewhere under similar circumstances. The second part of the article will consider laboratory quality control as practiced in the UK and as recommended in the second edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. These evidence-based guidelines provide recommendations for organising and monitoring quality control as well as for introducing new technology and standardising terminology, which are equally relevant for new and existing programmes. Invasive cancer audit may highlight areas where procedures could be improved in any programme but also can also demonstrate the effectiveness of screening.


Assuntos
Programas de Rastreamento/estatística & dados numéricos , Controle de Qualidade , Neoplasias do Colo do Útero/diagnóstico , Adulto , Idoso , Feminino , Diretrizes para o Planejamento em Saúde , Humanos , Incidência , Programas de Rastreamento/métodos , Programas de Rastreamento/tendências , Pessoa de Meia-Idade , Reino Unido/epidemiologia , Neoplasias do Colo do Útero/epidemiologia
11.
Diagn Cytopathol ; 34(9): 649-58, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16900463

RESUMO

Precise localization and diagnosis of pancreatic endocrine tumors (PETs) is important, because pancreatic PETs have different clinical and biological behavior and treatment modalities than do exocrine pancreatic tumors. In contrast to the much more common exocrine adenocarcinomas, cytologic studies of PET are relatively rare and many cytopathologists lack experience with the cytomorphologic features of these tumors.During the last 10 yr, endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has matured into an accurate, highly sensitive, and cost-effective modality for the preoperative localization of pancreatic PETs. This has resulted in an increased number of PETs first sampled as cytology specimens. This manuscript focuses on the cytomorphologic features most suggestive of pancreatic PETs, differential diagnosis, and diagnostic pitfalls of PETs. The technical development of EUS-guided FNA and the ancillary studies for pancreatic PETs are also reviewed. The data summarized in this review indicate that EUS-FNA is a valuable method in the recognition of pancreatic PETs and in most cases cytopathologists could reach a correct diagnosis of these tumors, including their hormone producing capability on aspirated cytologic material.


Assuntos
Biópsia por Agulha Fina/métodos , Carcinoma de Células das Ilhotas Pancreáticas/patologia , Endoscopia do Sistema Digestório/métodos , Insulinoma/patologia , Neoplasias Pancreáticas/patologia , Ultrassonografia/métodos , Adenocarcinoma Papilar/patologia , Biomarcadores Tumorais/análise , Carcinoma de Células Acinares/patologia , Carcinoma de Células das Ilhotas Pancreáticas/química , Carcinoma Ductal Pancreático/patologia , Diagnóstico Diferencial , Gastrinoma/química , Gastrinoma/patologia , Glucagonoma/química , Glucagonoma/patologia , Humanos , Imuno-Histoquímica , Insulinoma/química , Linfoma/patologia , Neoplasias Pancreáticas/química
16.
PLoS One ; 6(9): e25191, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21949883

RESUMO

EGFR mutations correlate with improved clinical outcome whereas KRAS mutations are associated with lack of response to tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). Endobronchial ultrasound (EBUS)-transbronchial needle aspiration (TBNA) is being increasingly used in the management of NSCLC. Co-amplification at lower denaturation temperature (COLD)-polymerase chain reaction (PCR) (COLD-PCR) is a sensitive assay for the detection of genetic mutations in solid tumours. This study assessed the feasibility of using COLD-PCR to screen for EGFR and KRAS mutations in cytology samples obtained by EBUS-TBNA in routine clinical practice. Samples obtained from NSCLC patients undergoing EBUS-TBNA were evaluated according to our standard clinical protocols. DNA extracted from these samples was subjected to COLD-PCR to amplify exons 18-21 of EGFR and exons two and three of KRAS followed by direct sequencing. Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)). Molecular analysis of all EGFR and KRAS target sequences was achieved in 126 of 132 (95.5%) and 130 of 132 (98.4%) of cases respectively. EGFR mutations were identified in 13 (10.5%) of fully evaluated cases (11 in adenocarcinoma and two in NSCLC-NOS) including two novel mutations. KRAS mutations were identified in 23 (17.5%) of fully analysed patient samples (18 adenocarcinoma and five NSCLC-NOS). We conclude that EBUS-TBNA of lymph nodes infiltrated by NSCLC can provide sufficient tumour material for EGFR and KRAS mutation analysis in most patients, and that COLD-PCR and sequencing is a robust screening assay for EGFR and KRAS mutation analysis in this clinical context.


Assuntos
Brônquios/diagnóstico por imagem , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/genética , Receptores ErbB/genética , Mutação/genética , Reação em Cadeia da Polimerase/estatística & dados numéricos , Proteínas Proto-Oncogênicas/genética , Proteínas ras/genética , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Idoso , Idoso de 80 Anos ou mais , Biópsia por Agulha Fina , Carcinoma de Células Grandes/diagnóstico , Carcinoma de Células Grandes/genética , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/genética , DNA de Neoplasias/genética , Endossonografia , Estudos de Viabilidade , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Prognóstico , Proteínas Proto-Oncogênicas p21(ras)
18.
Mod Pathol ; 20(4): 482-96, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17334349

RESUMO

Synovial Sarcoma consistently harbors t(X;18) resulting in SS18-SSX1, SS18-SSX2 and rarely SS18-SSX4 fusion transcripts. Of 328 cases included in our study, synovial sarcoma was either the primary diagnosis or was very high in the differential diagnosis in 134 cases: of these, amplifiable cDNA was obtained from 131. SS18-SSX fusion products were found in 126 (96%) cases (74 SS18-SSX1, 52 SS18-SSX2), using quantitative and 120 by conventional reverse transcriptase-polymerase chain reaction (RT-PCR). One hundred and one cases in a tissue microarray, analyzed by fluorescence in situ hybridization (FISH), revealed that 87 (86%) showed SS18 rearrangement: four RT-PCR positive cases, reported as negative for FISH, showed loss of one spectrum green signal, and 15 cases had multiple copies of the SS18 gene: both findings are potentially problematic when interpreting results. One of three cases, not analyzed by RT-PCR reaction owing to poor quality RNA, was positive by FISH. SS18-SSX1 was present in 56 monophasic and 18 biphasic synovial sarcoma: SS18-SSX2 was detected in 41 monophasic and 11 biphasic synovial sarcoma. Poorly differentiated areas were identified in 44 cases (31%). There was no statistically significant association between biphasic, monophasic and fusion type. Five cases were negative for SS18 rearrangement by all methods, three of which were pleural-sited neoplasms. Following clinical input, a diagnosis of mesothelioma was favored in one case, a sarcoma, not otherwise specified in another and a solitary fibrous tumor in the third case. The possibility of a malignant peripheral nerve sheath tumor could not be excluded in the other two cases. We concluded that the employment of a combination of molecular approaches is a powerful aid to diagnosing synovial sarcoma giving at least 96% sensitivity and 100% specificity but results must be interpreted in the light of other modalities such as clinical findings and immunohistochemical data.


Assuntos
Antígenos de Neoplasias/metabolismo , Proteínas de Neoplasias/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Repressoras/metabolismo , Sarcoma Sinovial/metabolismo , Neoplasias de Tecidos Moles/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Neoplasias/genética , Biomarcadores Tumorais/metabolismo , Criança , Pré-Escolar , Feminino , Formaldeído , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/genética , Proteínas de Fusão Oncogênica/genética , Proteínas de Fusão Oncogênica/metabolismo , Inclusão em Parafina , Proteínas Proto-Oncogênicas/genética , RNA Mensageiro/metabolismo , Proteínas Recombinantes de Fusão/genética , Proteínas Repressoras/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sarcoma Sinovial/genética , Sarcoma Sinovial/patologia , Neoplasias de Tecidos Moles/genética , Neoplasias de Tecidos Moles/patologia , Análise Serial de Tecidos , Fixação de Tecidos
19.
J Gen Virol ; 84(Pt 5): 1063-1070, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12692269

RESUMO

Human papillomavirus type 16 (HPV-16) L1- and E7-specific T cell responses were measured in 58 women with abnormal cervical cytology in a prospective study. On recruitment, patients responded most frequently and with the highest numbers of responding cells to the L1 region aa 311-345 and this response was significantly associated with the presence of cervical disease (P=0.041). Responses to the L1 peptide aa 281-295 were significantly higher in patients with CIN III than in those with HPV/CIN I or CIN II lesions (P=0.027). The E7 region aa 70-98 was the most immunogenic in patients with squamous intraepithelial lesions of the cervix (SIL) but the responses detected were not significantly higher than in patients without SIL. Following treatment, the T cell response profiles of patient groups did not change significantly. However, on analysis of the responses of individual patients with and without recurrent disease on follow-up, significant differences were found. Recurrence of disease was associated with T cell responses to the E7 region aa 70-98 at the patient's first clinic visit (P=0.017). Recurrence of disease was also accompanied by an increase in the total number of L1-specific short-term T cell lines (STLs) at follow-up, whereas absence of disease was accompanied by a decrease in L1-specific STLs. The data also suggested a possible link between E7 70-98-specific responses and acquisition of disease by patients who were previously disease-free. Further studies are warranted to determine whether this response could be useful as a marker of recurrent disease in some patients.


Assuntos
Proteínas do Capsídeo , Papillomaviridae/imunologia , Linfócitos T/imunologia , Doenças do Colo do Útero/tratamento farmacológico , Doenças do Colo do Útero/fisiopatologia , Displasia do Colo do Útero/fisiopatologia , Neoplasias do Colo do Útero/fisiopatologia , Células Cultivadas , Feminino , Humanos , Ativação Linfocitária , Proteínas Oncogênicas Virais/administração & dosagem , Proteínas Oncogênicas Virais/química , Proteínas Oncogênicas Virais/imunologia , Papillomaviridae/genética , Papillomaviridae/patogenicidade , Proteínas E7 de Papillomavirus , Infecções por Papillomavirus/imunologia , Infecções por Papillomavirus/fisiopatologia , Infecções por Papillomavirus/virologia , Peptídeos/síntese química , Peptídeos/imunologia , Estudos Prospectivos , Recidiva , Infecções Tumorais por Vírus/imunologia , Infecções Tumorais por Vírus/fisiopatologia , Infecções Tumorais por Vírus/virologia , Doenças do Colo do Útero/imunologia , Doenças do Colo do Útero/virologia , Neoplasias do Colo do Útero/imunologia , Neoplasias do Colo do Útero/virologia , Displasia do Colo do Útero/imunologia , Displasia do Colo do Útero/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA